Pancreatic cancer therapy Phase 2 underway

|By:, SA News Editor

OncoMed Pharmaceuticals (NASDAQ:OMED) commences patient dosing in its randomized placebo-controlled 124-patient Phase 2 clinical trial evaluating the safety and efficacy of OMP-59R5 (tarextumab) in patients with pancreatic cancer. Tarextumab is being tested in combination with Abraxane (paclitaxel) plus gemcitabine in patients with previously untreated stage IV pancreatic cancer. The primary endpoint is progression-free survival (PFS) compared to placebo.

The one-year survival rate for newly diagnosed patients is only 20%.